Thursday 26 January 2023

US-based biopharmaceutical company Longevity Biomedical, Inc, which is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions to increase human health span, and special purpose acquisition Company Denali Capital Acquisition Corp have entered into a definitive business combination agreement, the companies said.

Upon closing of the transaction pursuant to the BCA, the combined company will operate as Longevity Biomedical, Inc. and is expected to list on NASDAQ under the ticker symbol "LBIO."